PMID- 35649528
OWN - NLM
STAT- MEDLINE
DCOM- 20221006
LR  - 20221006
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 10
DP  - 2022 Oct
TI  - Effectiveness and safety of sacubitril/valsartan for patients with hypertension 
      and heart failure in the real-world setting: A retrospective study in China.
PG  - 1539-1547
LID - 10.1111/jcpt.13699 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Hypertension (HP) is associated with heart failure 
      (HF). Sacubitril/valsartan (sac/val) has been approved for primary HP by China 
      Food and Drug Administration (CFDA) in June 2021. The present study aimed to 
      provide evidence on the effectiveness and safety of sac/val in Chinese patients 
      complicated with HP and HF. METHODS: This retrospective study was conducted on 
      adult patients diagnosed with HP and HF and treated with sac/val between July 
      2020 and December 2020. The potential risk factors for the discontinuation events 
      caused by sac/val-related adverse events (AEs) were explored. The data, including 
      blood pressure (BP), cardiac indicators, corresponding values on 
      echocardiographic parameters, unplanned visits, and AEs throughout 3-12 months, 
      were collected. RESULTS AND DISCUSSION: A total of 446 eligible patients were 
      included in this study. The discontinuation events of sac/val were mainly 
      attributed to its AEs (hypotension, hyperkalemia, and deterioration in kidney 
      function). Univariate analysis revealed that history of chronic kidney disease, 
      atrial fibrillation, higher values of serum creatinine, serum uric acid, serum 
      N-terminal pro B-type natriuretic peptide, and lower estimated glomerular 
      filtration rate were potential risk factors for discontinuation. Patients who 
      maintained sac/val therapy throughout 3-12 months showed significantly improved 
      values of clinical BP, cardiac indicators, and echocardiographic parameters 
      compared to those at baseline (p < 0.0001). WHAT IS NEW AND CONCLUSION: Sac/val 
      was effective on BP and improved cardiac function in patients complicated with HP 
      and HF. The physicians should focus on patients with renal dysfunction to take 
      timely precautions to improve tolerability for sac/val.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Zuo, Chengchun
AU  - Zuo C
AUID- ORCID: 0000-0003-0167-4931
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Li, Xiaoye
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Fan, Linlin
AU  - Fan L
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Tian, Dan
AU  - Tian D
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Chen, Can
AU  - Chen C
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Li, Xiaoyu
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Lv, Qianzhou
AU  - Lv Q
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
GR  - SHYXH-ZP-2021-002/Clinical comprehensive evaluation and treatment management 
      pathway of sav/val in the real world of hypertensionnicipal Health Commission/
PT  - Journal Article
DEP - 20220601
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 17ERJ0MKGI (sacubitril)
RN  - 268B43MJ25 (Uric Acid)
RN  - 80M03YXJ7I (Valsartan)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aminobutyrates/adverse effects
MH  - Angiotensin Receptor Antagonists/adverse effects
MH  - Biphenyl Compounds/adverse effects
MH  - Creatinine
MH  - Drug Combinations
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Natriuretic Peptide, Brain/therapeutic use
MH  - Retrospective Studies
MH  - Tetrazoles/adverse effects
MH  - Uric Acid
MH  - Valsartan/therapeutic use
OTO - NOTNLM
OT  - China
OT  - heart failure
OT  - hypertension
OT  - sacubitril/valsartan
EDAT- 2022/06/02 06:00
MHDA- 2022/10/07 06:00
CRDT- 2022/06/01 20:23
PHST- 2022/04/05 00:00 [revised]
PHST- 2022/03/15 00:00 [received]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/10/07 06:00 [medline]
PHST- 2022/06/01 20:23 [entrez]
AID - 10.1111/jcpt.13699 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Oct;47(10):1539-1547. doi: 10.1111/jcpt.13699. Epub 2022 
      Jun 1.